Human Fetal Progenitor Tenocytes for Regenerative Medicine. by Grognuz, A. et al.
Cell Transplantation, Vol. 25, pp. 463–479, 2016 0963-6897/16 $90.00 + .00
Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/096368915X688515
Copyright Ó 2016 Cognizant, LLC. E-ISSN 1555-3892
 www.cognizantcommunication.com
463
Received April 23, 2015; final acceptance September 3, 2015. Online prepub date: June 24, 2015.
Address correspondence to Professor Lee Ann Laurent-Applegate, University Hospital of Lausanne (CHUV), Service of Plastic, Reconstructive and 
Hand Surgery, Regenerative Therapy Unit (UTR), EPCR/Croisettes 22, CH-1066 Epalinges, Switzerland. Tel: + 41 21 314 35 10; Fax: + 41 21 887 84 14; 
E-mail: Lee.Laurent-Applegate@chuv.ch
Human Fetal Progenitor Tenocytes for Regenerative Medicine
A. Grognuz,* C. Scaletta,* A. Farron,† W. Raffoul,* and L. A. Applegate*
*Unit of Regenerative Therapy, Service of Plastic, Reconstructive and Hand Surgery, 
Department of Musculoskeletal Medicine, University Hospital of Lausanne, Switzerland
†Service of Orthopaedics and Traumatology, Department of Musculoskeletal Medicine, 
University Hospital of Lausanne, Switzerland
Tendon injuries are very frequent and affect a wide and heterogeneous population. Unfortunately, the healing 
process is long with outcomes that are not often satisfactory due to fibrotic tissue appearance, which leads to 
scar and adhesion development. Tissue engineering and cell therapies emerge as interesting alternatives to 
classical treatments. In this study, we evaluated human fetal progenitor tenocytes (hFPTs) as a potential cell 
source for treatment of tendon afflictions, as fetal cells are known to promote healing in a scarless regenerative 
process. hFPTs presented a rapid and stable growth up to passage 9, allowing to create a large cell bank for 
off-the-shelf availability. hFPTs showed a strong tenogenic phenotype with an excellent stability, even when 
placed in conditions normally inducing cells to differentiate. The karyotype also indicated a good stability up to 
passage 12, which is far beyond that necessary for clinical application (passage 6). When placed in coculture, 
hFPTs had the capacity to stimulate human adult tenocytes (hATs), which are responsible for the deposition 
of a new extracellular matrix during tendon healing. Finally, it was possible to distribute cells in porous or gel 
scaffolds with an excellent survival, thus permitting a large variety of applications (from simple injections to 
grafts acting as filling material). All of these results are encouraging in the development of an off-the-shelf cell 
source capable of stimulating tendon regeneration for the treatment of tendon injuries.
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INTRODUCTION
Tendons have the role to transmit forces from muscle 
to bone and protect the surrounding tissues by working as 
buffers against tension and compression. Unfortunately, 
tendon injuries are very common and affect wide and 
heterogeneous populations, which leads to potential loss 
of activity due to decreased mobility and chronic pain. 
Tendon injuries can be divided into two main categories 
depending on their acute or chronic nature; acute afflic-
tions usually include traumatic partial or total tears or 
avulsions, while chronic afflictions are due to an overuse 
degenerative process presently referred to as tendinopa-
thies (49). Although there is a wide range of tendinopa-
thies, the majority are due to tendinosis (35). In this case, 
the histopathological observations of overused tendons 
generally present a disorganized extracellular matrix 
with separation of collagen fibers, decrease in fiber diam-
eter and in density, but increase in type III collagen and 
in glycosaminoglycans. Simultaneously, hypercellularity 
and neovascularization are detected, but inflammation 
and granulation tissues are not common and are nor-
mally only seen in tendon ruptures. Subcategories of 
tendinosis showing lipoid degeneration or calcifications 
between collagen fibers can also be found (34,46,49). 
However, the separation between acute and degenera-
tive tendon injuries is not always clear as spontaneous 
ruptures appear almost always from degenerative states, 
and thus tendinopathies can be considered as a predis-
position to tendon ruptures (28,33). In many countries, 
with the democratization of sport practice, the number of 
overuse injuries has augmented during the last decades, 
and frequent sport-related injuries to tendons include the 
Achilles, the patellar, the tractus iliotibialis, the biceps 
femoris (Hamstring syndrome), the rotator cuff, the com-
mon wrist extensors (tennis elbow), and the common 
wrist flexors (golfer’s elbow) (21,39). From a large joint 
clinical database, it has been shown that for 100.4 mil-
lion injuries of any kind reported in 2006/2007 in the US, 
about 61.2 million are musculoskeletal, and among them, 
44% are due to sprains and strains of soft tissue including 
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ligaments or tendons (54). Taking results globally in the 
US, surgical interventions to repair tendons were esti-
mated at 51,000 per year for rotator cuff tendons, 44,000 
for Achilles tendon, and 42,000 for patellar tendon (11). 
Acute injuries to the hand tendon system also represent 
numerous cases (53). Globally, a variety of tendons are 
implicated with frequent impact on work or leisure.
The conventional treatments depend on the grav-
ity of the injury, but range from conservative treatments 
with physiotherapy or infiltration and extend to surgical 
interventions such as tenotomy, tenodesis, suture, trans-
fer, graft, or even prosthetic implants. Controlled mobi-
lization is recommended in parallel because it has been 
shown that mechanical stimulation leads to fewer adhe-
sions and increased strength (27). Regardless, tendon 
healing is always long, and this process can be divided in 
three overlapping steps. At first the inflammatory phase 
starts immediately following injury with the synthesis of 
chemoattractive substances by erythrocytes and inflam-
matory cells to attract and stimulate tenocytes. After a few 
days, the second step consists in the production of matrix 
mostly composed of type III collagen and under the control 
of tenocytes and macrophages. The last step takes place 
after 1 or 2 months; extracellular matrix proteins are still 
produced, but with an increase in type I collagen deposi-
tion and the reorganization and optimization of the fiber 
alignment. With time, the cell density and activity dimin-
ishes, and the overall procedure can take as long as 1 year 
or more. Unfortunately, even if long, the healing process 
is not perfect, and the natural structure is never attained 
again. Instead, scar tissue and adhesions remain and can 
lead to decreased mobility and rerupture (27,49,55).
Along with diminished healing outcomes, another 
issue is the potential lack of material for tissue replace-
ment. For example, in the case of hand tendon injuries, 
a graft is frequently needed. The harvest of the palmaris 
longus or plantaris tendon is the prime choice as other 
graft sites potentially lead to disability. Nevertheless, 
these two sources are vestigial muscles, and thus are 
sometimes absent in individuals (26,56) and even if pres-
ent are often not adequate (22,26).
To counter the poor healing outcomes and the poten-
tial lack of material, new strategies must be explored and 
tested. The field of regenerative therapy has encountered 
much interest lately. Off-the-shelf methods of cellular 
therapies able to stimulate tendon regeneration while 
preventing scar tissue maintenance would be of particu-
lar interest. It has been well documented in animals and 
humans that the early to midgestation fetuses (<24 weeks 
gestation for human) heal wounds through a mechanism 
that differs from adult tissue and is more rapid and leads 
to a regenerated tissue without scar (1), which is intrinsic 
to the fetal tissue itself and not to the fetal environment 
(10,14,20). It was shown in fetal animal models that bone 
(30), articular cartilage (37), and tendon (8) have the same 
ability as the skin to heal without scar. A recent study 
highlighted the change in expression of multiple genes 
during tendon development, which could explain the dif-
ferent type of healing (48). In the same manner, the use of 
cells harvested from fetal tissue has proven to be positive 
in wound healing. Two clinical trials including pediatric 
patients suffering from burns or wounds obtained excel-
lent functional and esthetical results with the use of bio-
logical bandages composed of fetal skin progenitor cells. 
The damaged sites stimulated by fetal fibroblasts healed 
so well that the autografts initially intended were finally 
not necessary (15,23). In another study on adults suffer-
ing from refractory venous ulcers, the use of fetal skin 
progenitor cells also improved the healing (45). Along 
with their ability to stimulate healing, fetal cells present 
other interesting characteristics. They are already tissue 
specific and thus have innate good phenotypic stability. 
Moreover, with their high proliferation capacity, it is nota-
bly possible to create large cell stocks (cell banks) show-
ing a high level of consistency and safety with respect 
to stringent requirements for clinical practice. Indeed, as 
the cell bank can be based on only one donor tissue, it is 
possible to trace all levels of the process from tissue to 
cells to final preparations including extensive screening 
for infectious diseases (2,44).
Therefore, fetal cells with their off-the-shelf availabil-
ity and their capacity to stimulate healing in a scarless 
manner are a very attractive source for tissue regeneration. 
In this study, we evaluate the characteristics of human 
fetal progenitor tenocytes (hFPTs) that have undertaken 
clinical processing as these cells could be a potential safe 
and stable source of therapeutic cells available for tissue 
engineering and for treatment of tendon injuries.
MATERIALS AND METHODS
Tissue Culture and Cell Banking
Human Fetal Progenitor Tenocyte Harvesting and 
Cell Banking. Human fetal progenitor tenocytes were iso-
lated from the Achilles tendon of a male 14 week gesta-
tion organ donation according to a protocol approved by 
an ethics committee [University Hospital of Lausanne 
(CHUV), Ethics Committee Protocol No. 62/07: 14 week 
gestation organ donation, registered under the Federal 
Transplantation Program and its Biobank complying with 
the laws and regulations]. The procedure was already 
explained in detail for other tissues (3,44). Briefly, the 
tendon biopsy of approximately 1 mm3 was dissected by a 
fetal pathologist and placed in phosphate-buffered saline 
(PBS: NaCl 6.8 g/L, Na2HPO4 1.5 g/L, KH2PO4 0.4 g/L, 
code No. 100 0 324; Bichsel, Interlaken, Switzerland). 
Within several hours, the biopsy was transported to the 
certified human tissue laboratory for cell culture for 
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clinical use. The biopsy was washed three times for 15 
min in PBS with 1% penicillin–streptomycin (Pen-Strep: 
code No. 15140-122; Gibco, Life Technologies Ltd., 
Paisley, UK). The tissue was dissected into smaller frag-
ments, placed into culture dishes of 10 cm diameter (TPP, 
Trasadingen, Switzerland), and cultured in clinical growth 
medium composed of Dulbecco’s modified Eagle medium 
(DMEM, code No. 41966-029; Gibco) containing 25 mM 
dextrose, 1 mM sodium pyruvate, supplemented to 5.97 
mM l-glutamine (l-glut: code No. 25030-024; Gibco) and 
with 10% clinical-grade fetal bovine serum (FBS, code 
No. 10101145; Invitrogen, Life Technologies Ltd), with-
out antibiotic supplementation. The medium was changed 
every 3 to 4 days and first cell growth emitting from tissue 
was seen already at 24 h. These cells (passage 0) were 
grown to 50% confluence, detached with trypsin-ethylene-
diaminetetraacetic acid (trypsin-EDTA: 0.05% trypsin–
0.02% EDTA, code No. 25300-054; Gibco), distributed 
into 75-cm2 flasks (TPP) at passage 1, and they were used 
to develop a parental cell bank 11 days later when they 
reached full confluence. A total of 50 cryovials, each with 
10 million cells in 1 ml cryosolution [50% DMEM, 40% 
FBS, 10% dimethyl sulfoxide (DMSO: code No. D2438; 
Sigma-Aldrich, St. Louis, MO, USA)], were frozen at a 
cooling rate of 1°C/min within a Nalgene cryo freezing 
container placed at −80°C. After 24 h, cells were trans-
ferred to the vapor phase of liquid nitrogen (−165°C) for 
long-term storage. The developed process has provided a 
unique cell population with the associated cell deposits 
for patent application (WO 2013/008174 A1: European 
publication No. 2732030: European Collection of Cell 
Cultures, ECACC deposit reference 12070302).
Human Adult Tenocyte (hAT) Harvesting and Cell 
Banking. Adult tenocytes can be harvested from pieces 
of tendon resected during an operation. As Achilles ten-
don is generally not resected, it was decided to work 
with another anatomical source more readily available. 
Healthy abductor pollicis longus tendon of a 69-year-old 
male donor was obtained in the CHUV in accordance with 
the institutional policy on tissue donation and under the 
Department Biobank regulations (CHUV, Regulations for 
Biobank for Musculoskeletal Medicine Department No. 
3-12-2012). Tissue was placed in PBS and directly trans-
ferred to the laboratory. The tissue fragment was rinsed 
three times for 15 min in PBS with 5% Pen-Strep. It was 
then dissected into smaller fragments and transferred into 
dishes of 6 cm diameter with growth medium (further 
called standard growth medium) composed of DMEM 
containing 25 mM dextrose, 1 mM sodium pyruvate, 
5.97 mM l-glut, and 10% laboratory-grade FBS (code No. 
F7524; Sigma-Aldrich), without antibiotic supplementa-
tion. The cells could be seen to migrate from the tissue 
after several days (5–7), and the medium was changed 
every 3 to 4 days. At confluency, cells were detached with 
trypsin–EDTA and grown in 75-cm2 flasks up to passage 
2 to develop a standard cell stock. Cells were trypsinized 
and distributed into 24 vials, each with 1 million cells in 
1 ml cryosolution (50% DMEM, 40% FBS, 10% DMSO) 
and frozen in the same manner as for hFPTs (lower cell 
concentration to obtain sufficient number of vials). A 
parental adult cell bank composed of 24 million cells in 
passage 2 was therefore created.
Cell Growth and Morphology: 2D and 3D Conditions
Both human fetal progenitor and adult tenocytes were 
grown under the same conditions for 2D culture. Cells 
were expanded into tissue culture polystyrene flasks of 
75 cm2 with filter screw cap (TPP) placed in cell culture 
incubators at 37°C in a humidified atmosphere containing 
5% CO2. The standard growth medium was composed of 
DMEM with 25 mM dextrose, 1 mM sodium pyruvate, 
5.97 mM l-glutamine, and 10% laboratory-grade FBS, 
free of antibiotic supplementation. It was changed every 
3 to 4 days, and cells were trypsinized when reaching 
confluence. Seeding densities of 3,000 and 6,000 cells/
cm2 were tested, but as higher seeding densities did not 
accelerate the overall growth, cells were then seeded at 
the low density of 3,000 cells/cm2. Cell growth of hFPTs 
in 2D standard culture conditions was analyzed between 
passage 4 and 15. The morphology was controlled and 
recorded every 3 to 4 days by imaging (CKX41 and 
E-330; Olympus, Tokyo, Japan). After 13–15 days of 
growth, cells of at least three flasks were trypsinized, 
pooled together, and counted. The series were repeated 
multiple times, and each passage was evaluated at least 
four times. Mean population doublings (PD) and dou-
bling time (DT) were determined for each passage using 
the formulas:
 
 
 
 =
final cell number
ln
initial cell number
ln(2)
PD  (1)
 
=
[d]Time
DT
PD
 (2)
The linearity of the lengthening in doubling time for 
late passages was evaluated statistically by determining 
the regression line with the root mean square error model 
and calculating the coefficient of determination (R2) in 
excel software (Microsoft, Redmond, WA, USA).
hFPTs were also seeded in six wells at passages 4 
and 9, and the same formulas were used to determine 
the shortest doubling time during the most rapid growth 
period occurring between day 1 or 2 and day 7 of culture 
(each time point in triplicate and experiments repeated 
three times).
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For some experiments, the cells were also cultured as 
microtissue pellets with a 3D configuration. They were pro-
duced by centrifuging 500,000 cells for 10 min at 250 × g 
and then placing individual tubes in cell culture incubators 
at 37°C in a humidified atmosphere containing 5% CO2 with 
the cap unscrewed half a rotation to allow gas circulation. 
Standard growth medium was changed every 3 to 4 days. 
Some pellets were also produced with a supplementation of 
284 μM l-ascorbic acid (code No. A4544; Sigma-Aldrich) 
to evaluate the impact on protein deposition.
Cell Conservation, Viability, and Recovery
The cells were preserved in a standard cryosolution 
(50% DMEM, 40% FBS, and 10% DMSO) for long-term 
conservation. The percentage of living cells at thawing 
was based on cell counting with a hemocytometer and 
the trypan blue exclusion technique (code No. T-8154; 
Sigma-Aldrich). The cells were then plated in 75-cm2 
tissue culture flasks and counted when cells reached 
confluency (after 13 to 15 days in culture with a seeding 
density of 3,000 cells/cm2). The results were compared 
to cells seeded at the same passage from trypsinization 
instead of thawing.
Tendon Marker Profiling
hFPTs and hATs were both evaluated in 2D culture to 
compare their morphology and the expression of char-
acteristic markers. The cells were plated at 3,000 cells/
cm2 in 48-well plates and incubated under standard cul-
ture conditions for 72 h. Immunohistochemical stainings 
were then realized as follows. Permeabilization of mem-
branes was made during treatment for 10 min in 0.1% 
Triton X-100 (code No. A1388; Applichem, Darmstadt, 
Germany). The slides were washed three times in PBS 
and blocked for 30 min in bovine serum albumin solution 
1% (BSA: code No. A7906; Sigma-Aldrich), before incu-
bation with primary antibody at 4°C overnight. Primary 
antibodies were diluted in BSA 1% and targeted type I 
collagen (1:1,000; code No. ab292; Abcam, Cambridge, 
UK), scleraxis (1:100; code No. ab58655; Abcam), and 
tenomodulin (N-14) (1:100; code No. sc-49325; Santa 
Cruz Biotechnology, Heidelberg, Germany). After three 
washes in PBS, the slides were incubated with their 
complementary secondary antibody for 40 min at room 
temperature, namely Alexa Fluor® 488 donkey anti-goat 
IgG (1:800 in PBS; code No. A-11055; Molecular Probes, 
Life Technologies Ltd, Paisley, UK) or Alexa Fluor® 
568 donkey anti-rabbit IgG (1:1,000 in PBS; code No. 
A-10042; Molecular Probes). The nuclei were then coun-
terstained with 4,6-diamidino-2-phenylindole (DAPI; 
code No. 10236276001; Roche, Rotkreuz, Switzerland), 
and images were taken with an inverted microscope 
equipped for fluorescence (Olympus IX81) and a digital 
camera (Andor iXon). Control stainings were performed 
with the secondary antibodies only (primary antibodies 
replaced by 1% BSA) and were used as negative to adjust 
display of fluorescent signals within ImageJ software 
(NIH, Bethesda, MD, USA).
hFPTs and hATs were also grown in 3D pellet culture 
to evaluate their ability to produce tendon matrix. After 
14 days, pellets were fixed in 4% (w/v) neutralized for-
malin solution (code No. 3933; J.T. Baker, Deventer, The 
Netherlands) for 24 h at 4°C, washed three times with 
PBS, and subsequently dehydrated and embedded in 
paraffin (code No. 111609; Merck Millipore, Darmstadt, 
Germany). The sections of 3 μm were then rehydrated and 
washed with PBS prior to staining. Type I collagen, teno-
modulin, and scleraxis immunohistochemical stainings 
were realized with the same method as described above for 
monolayer cells, but with an additional step consisting of 
antigen retrieval for 10 min in heated Tris (hydroxymethyl)
aminomethane (Tris: 10 mM; code No. T-6066; Sigma-
Aldrich)–EDTA (1 mM; code No. 03680; Sigma-Aldrich) 
at pH 9.0, before blocking the section. Instead of addi-
tion of DAPI, the slides with 3D pellet culture were then 
mounted with Vectashield mounting medium with DAPI 
(code No. H-1200; Vector Laboratories, Burlingame, CA, 
USA). Control staining and treatment of images were done 
as explained above for 2D monolayer cells.
Cell Population Homogeneity and Stability: 
Flow Cytometry and Karyotyping
Population homogeneity and stability were evalu-
ated at passages 3, 6, and 9 by flow cytometry. Cells 
were tagged with ethidium monoazide (EMA: 1 μg/ml, 
code No. E1374; Molecular Probes) to exclude the cells 
with damaged membranes. Primary monoclonal mouse 
antibodies targeting fibroblast/epithelial marker D7-FIB 
(1:50 in PBS; code No. MCA1399GT, clone D7-FIB; 
Abd Serotec, Dusseldorf, Germany), macrophage/neu-
trophil marker CD14 (1:10; code No. MCA2185T, clone 
MEM-18; Abd Serotec), hematopoietic and endothelial 
cell marker CD34 (1:50; code No. MCA547GT, clone 
QBEND/10; Abd Serotec), cell adhesion marker CD90 
(1:10; code No. MCA90, clone F15-42-1; Abd Serotec), 
and the coreceptor of the transforming growth factor-b 
(TGF-b) superfamily CD105 (1:50; code No. MCA1557, 
clone SN6; Abd Serotec) were used. A secondary antibody, 
Alexa Fluor® 488 goat anti-mouse IgG (1:1,000 in PBS; 
code No. A-11001; Molecular Probes), was used in combi-
nation. Conjugated monoclonal antibodies were also used 
to tag human leukocyte antigens (HLA), which are impli-
cated in transplant rejection. HLA-DR, DP, DQ antibody 
was coupled with fluorescein isothyocyanate (FITC) and 
HLA-A, B, C antibody with phycoerythrin (PE) (1:1; code 
No. 555558, clone Tu39 and 555553, clone G46-2.6; BD 
Pharmingen, San Diego, CA, USA). The nonimmunogenic 
HLA-G protein was also tested with a primary monoclonal 
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mouse antibody (1:10; code No. ab52455, clone 4H84; 
Abcam) and with the same secondary antibody. Negative 
controls were made with nonspecific antibodies of the 
same isotypes at equal concentrations (Abd Serotec, code 
No. MCA928EL, code No. IC002P and BD Pharmingen, 
code No. 555573; R&D Systems, Minneapolis, MN, 
USA). Data were obtained with a CyAN™ADP analyzer 
(Beckman Coulter, Indian apolis, IN, USA) and processed 
with FlowJo software (Ashland, OR, USA).
A conventional karyotype was realized in order to 
observe potential numerical or structural abnormali-
ties and to identify low-degree mosaic conditions of the 
hFPTs. For these analyses, dividing cells were exposed 
for 1.5 h to colchicine (code No. 27650; Sigma-Aldrich) 
at a final concentration of 0.16 μg/ml to block cell divi-
sion in metaphase. The cells were then exposed to a 
hypotonic shock with 37.5 mM KCl (code No. 60121; 
Sigma-Aldrich) for 20 min, fixed with 25% acetic acid 
(code No. 320099; Sigma-Aldrich) and 75% methanol 
(code No. 179337; Sigma-Aldrich), and spread onto a 
glass microscope slide. The metaphases were exposed for 
10–20 s to trypsin (1% in EDTA), washed with 150 mM 
NaCl, and dried at room temperature. The slides were 
then stained with Giemsa solution (2% in PBS; code No. 
109204; Merck Millipore) for 8 min for visualization of 
the chromosomal G-band pattern. Karyotyping of hFPTs 
was accomplished with the observation of 60 metaphases 
at passages 3, 6, and 12. Forty supplementary metaphases 
were observed for chromosome 19 at passage 3.
Phenotypic Stability With Osteogenic- 
or Adipogenic-Inducing Condition
hFPTs were plated at 3,000 cells per cm2 in 12-well 
plates, alongside with human adipose-derived stem cells 
(ASCs) and human bone marrow-derived mesenchymal 
stem cells (BM-MSCs), both obtained in the CHUV in 
accordance with the institutional policy on tissue donation 
and under the Department Biobank regulations (CHUV, 
Ethics protocol No. 124/10: “Development of cell banks 
from bone marrow for the development of treatments 
and bioengineering” and Regulations for Biobank for 
Musculoskeletal Medicine Department of the CHUV No. 
3-12-2012). The cells were grown for 4 days with standard 
growth medium. An osteogenic induction was then accom-
plished over 21 days using a medium composed of a-MEM 
(code No. 22571-020; Gibco), 10% FBS, 5.97 mM l-glut, 
284 μM l-ascorbic acid, 5 mM b-glycerophosphate (code 
No. G9422; Sigma-Aldrich), and 100 nM dexamethasone 
(code No. D4902; Sigma-Aldrich), which was changed 
every 3 to 4 days. Cells were then rinsed with deionized 
water and fixed in 4% formalin solution for 10 min at room 
temperature before von Kossa staining (code Nos. 85228, 
S-4019, and S-1648; Sigma-Aldrich) or Alizarin red (pH 9) 
staining (code No. A5533; Sigma-Aldrich) to observe the 
production of mineralized matrix, with the first showing 
phosphate deposition and the second calcium deposition 
(43). An adipogenic induction was realized over 21 days 
using a medium composed of DMEM, 5.97 mM l-glut, 
1% insulin–transferrin–selenite (ITS, final concentration: 
10 mg/L bovine insulin, 5.5 mg/L human transferrin, and 
5 μg/L sodium selenite; code No. I3146; Sigma-Aldrich), 
1 μM dexamethasone, 100 μM indomethacin (code No. 
I7378; Sigma-Aldrich), and 100 μM 3-isobutyl-1-meth-
ylxanthine (IBMX, code No. I5879; Sigma-Aldrich). Cells 
were then rinsed with deionized water, fixed in 4% forma-
lin solution for 10 min at room temperature, and stained 
with Oil red O staining kit (code No. 010303; Diapath, 
Martinengo, Italy), according to the protocol of the manu-
facturer, to highlight the presence of neutral lipids.
Biocompatibility in Porous Scaffold and Gel Matrix
For evaluation of cell survival in porous scaffolds, 
hFPTs were trypsinized at passage 4, and solutions con-
taining 250,000 cells in 500 μl standard growth medium 
were inoculated onto solid 2.25 cm × 3 cm commercial 
horse collagen membranes (code No. B2240100999999; 
TissuFleece E, Baxter, Nuremberg, Germany) and placed 
in culture dishes of 10 cm diameter. After 1 h of incuba-
tion at 37°C and 5% CO2 to allow cells to attach to the 
membranes, standard growth medium was added in the 
dishes, which were then replaced in the incubator. At sev-
eral time points up to day 14, the membranes were rinsed 
with PBS and 250 μl of LIVE/DEAD solution (code No. 
L-3224; Molecular Probes) added over the entire mem-
branes. The membranes were incubated for 30 min at 
room temperature, before images were taken with an 
IX81 Olympus fluorescent microscope and Andor iXon 
digital camera and treated within ImageJ.
For evaluation of cell survival in hydrogel, hFPTs were 
trypsinized at passage 4, rinsed with PBS, and resuspended 
in PBS at 1 million cells/ml (PBS was used because growth 
medium cannot be removed from gel). Forty microliters 
was distributed into wells of a 96-well plate, mixed with 
60 μl of a commercial 0.8% hyaluronic acid (HA) gel 
(Sinovial, IBSA, Lodi, Italy) with a displacing pipette to 
homogenize the suspension, and the plate was placed at 
4°C overnight. After 24 and 72 h, 100 μl of LIVE/DEAD 
solution was added to the wells and mixed with the dis-
placing pipette. Images were taken after 30 min of incuba-
tion at room temperature and treated within ImageJ.
Growth-Stimulating Ability of hFPTs Toward hATs
A coculture assay was realized using hATs in a 12-well 
plate and g-irradiated hFPTs in Transwell inserts placed 
just above the hATs (code No. 3460-COR; Costar, Corning 
Incorporated, Lowell, MA, USA) (Fig. 1). The 0.4-μm 
polyester membrane at the bottom of Transwell allowed 
liquid diffusion while preventing any cell exchange. On 
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day minus 4 (−4D), hFPTs were irradiated with a dose of 
80 Gy (cesium 137) to inactivate their cellular division 
capacity in order to maintain a stable amount of cells in 
Transwells throughout the experiment (parallel test with-
out growth for four timepoints up to day 25). They were 
seeded in triplicates to test four conditions correspond-
ing to 0, 10,000, 50,000, and 100,000 irradiated hFPTs 
per Transwell with a total of 2 ml of standard growth 
medium between the well and Transwell. On day 0 (D0), 
the wells were all seeded at a density of 3,000 cells/cm2 
with adult cells. The 4-day delay between the two seeding 
sessions was done to already have a conditioned medium 
on day 0. The activity of hATs was measured every 3 to 4 
days up to day 17, and at each time point the Transwells 
were placed apart in incubator with 1 ml of conditioned 
medium, which was preserved. The medium remaining in 
wells was discarded, 500 μl standard growth medium and 
20 μl Cell Titer (code No. G3580; Promega, Madison, WI, 
USA) were added in each well (and in three supplemen-
tary empty wells for blanks), and the metabolic reaction 
took place during 30 min at 37°C. After 30 min, the reac-
tion was stopped by rapidly transferring the supernatants 
to an empty 12-well plate. The supernatants were then 
transferred into a 96-well plate, and 10 min after the end 
of reaction, the absorbance was read at 492 nm (Tecan 
Infinite F50, Männerdorf, Switzerland), the blank absor-
bance was subtracted, and the mean corrected absorbance 
was calculated for the three wells of each condition. The 
percentage increase in activity was also calculated for 
each condition in comparison to hATs without stimula-
tion. The hATs were rinsed once with PBS, 1 ml of stan-
dard growth medium was added to the wells, and the 
corresponding Transwells with 1 ml conditioned medium 
were placed back in the plate and into the incubator until 
the next time point. The whole experiment was performed 
three times successively, and the results are presented as 
mean of the three experiments with error bars indicating 
standard deviation. For each experiment and each condi-
tion, the average increase throughout the five timepoints 
was calculated, and the global increase per condition was 
then determined for the three experiments.
RESULTS
Cell Harvesting, Cell Culture, and Cell Banking
From one single fetal tendon biopsy, it was possible 
to isolate hFPTs and to expand them to obtain a clinical 
cell bank consisting of 50 vials of 10 million cells each 
at the end of passage 1. Starting from the adult pollicis 
longus tendon biopsy, it was possible to create a cell bank 
of 24 vials of 1 million cells each at the end of passage 
2. Concerning the morphology, hFPTs maintained very 
similar spindle-shaped morphology from low passages 
up to passage 12 with highly aligned configuration when 
Figure 1. Coculture method for stimulation assay. Coculture method employed to assess metabolic activity of human adult tenocytes 
(hATs) when stimulated by human fetal progenitor tenocytes (hFPTs). hFPTs irradiated (to block division) and placed in Transwell 
inserts 4 days (−4D) before hATs to already condition the medium. hATs seeded in wells on D0 for beginning of growth. Cell titer assay 
done on hATs with fresh medium, and supernatant transferred into 96-well plate after reaction for absorbance reading at 492 nm.
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the density increased. In higher passages (passage 15), 
the cells were slightly larger, and there was weaker cel-
lular alignment when the density increased (Fig. 2A). The 
mean doubling time of hFPTs during passage showed 
two different phases. From passage 3 to passage 9, the 
growth was very steady, and the mean doubling time 
was always more rapid than 4 days (mean = 3.75 days, 
SD 0.16 days) with a mean of 3.72 population doubling 
per passage (SD 0.18 PD). The minimal doubling time 
was recorded between day 1 or 2 and day 7 and was also 
very similar between passage 4 (mean = 1.2 days SD 0.2 
days, n = 3) and passage 9 (mean = 1.3 days, SD 0.1 days, 
n = 3). From passage 10 to passage 15, the proliferation 
rate slightly decreased linearly (R2 = 0.94). For each pas-
sage, one population doubling took an additional 8 h than 
in the previous passages to be achieved, which represents 
Figure 2. hFPT growth in monolayer culture. Cellular morphology of human fetal progenitor tenocytes (hFPTs) during cellular 
growth from low seeding density to confluency during early (P4–9), mid (P12), and late passages (P15) (A). Doubling time of hFPTs 
accomplished from early passages to late end-of-passage culture. Each passage tested four times with average number of days to allow 
cell doubling presented with standard deviation (B). Doubling time of hFPTs compared to the one of adult tenocytes (hATs) at similar 
passages (C). Influence on cell growth depending on low to intermediate seeding densities represented by actual cell counts from 0 to 
24 days of culture. Experimentation done in triplicate with average and standard deviation indicated (D). Scale bars: 100 μm.
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around 8.5% increase in doubling time (Fig. 2B). In 
comparison, hATs have already a longer doubling time 
at passage 4 with a mean of 4.40 days per doubling (SD 
0.21 days, n = 4), which then slows down to 5.38 days 
(SD 0.99 days, n = 3) at passage 6 and 6.54 days (SD 0.21 
days, n = 2) at passage 8 (Fig. 2C). It was shown that low 
seeding densities (3,000 cells/cm2) could be implemented 
with hFPTs with results very similar to higher seeding 
densities (6,000 cells/cm2) (Fig. 2D). Low seeding densi-
ties allowed for a rapid early expansion and development 
of a very large clinical cell bank.
Cell Conservation, Viability, and Recovery
hFPTs conditioned in freezing medium and frozen at 
−80°C in passage 3 for 4 to 10 months presented a sur-
vival rate of 97.6% (SD 0.6%, n = 5) after thawing. When 
seeded in 75-cm2 flasks at passage 4 for 14 days, they had 
a mean doubling time of 3.73 days (SD 0.13 days, n = 3), 
which is very close to what is found for the same pas-
sage from enzymatic detachment with 3.62 days (SD 0.42 
days, n = 2). hFPTs frozen in the vapor phase of liquid 
nitrogen for 30 to 36 months presented a survival rate of 
93.8% (SD 2.9%, n = 3) and a mean doubling time of 3.43 
days (SD 0.21 days, n = 3).
Expression of Surface Markers in 2D 
and 3D Culture Conditions
When cultured in 2D monolayer culture, fetal progeni-
tor and adult tenocytes presented a very similar spindle-
shaped morphology, and both expressed the three different 
markers. The normally extracellular type I collagen was 
present in the cytoplasm, but not in the nucleus. The type 
II transmembrane protein tenomodulin was expressed 
over the entire surface. The transcription factor scleraxis 
was detectable as a light staining both within the nucleus 
and in close proximity (Fig. 3A).
Figure 3. hFPT immunohistochemical staining in 2D and 3D (compared to hAT). Immunohistochemical staining of human fetal 
progenitor tenocytes (hFPTs) and adult tenocytes (hATs) for collagen I (COL1), tenomodulin (TENO), and scleraxis (SCX) in 2D 
monolayer culture (A) and 3D pellet culture with (+) or without (−) ascorbic acid supplementation (B). Negative controls shown in 
upper right corner of images. Scale bars: 100 μm.
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Human progenitor and adult tenocytes had both the 
ability to form 3D pellets, and in such a configuration they 
were able to deposit extracellular matrix during the cre-
ation of microtissues. The matrix-to-cell ratio was slightly 
higher in hFPT pellets with the nucleus appearing more 
distant with more matrix in between. Interestingly, type 
I collagen was only detectable in the extracellular matrix 
surrounding fetal progenitor cells, but not around adult 
cells. The supplementation of the medium with ascorbic 
acid allowed to detect type I collagen also with hATs, but 
still in lower quantity compared to hFPTs. Tenomodulin 
(extracellular domain) was positive both in progenitor and 
adult tenocytes. Scleraxis is not an extracellular matrix pro-
tein, but was also tested in 3D to evaluate its expression. 
Although visible in monolayer culture, we were not able to 
detect the presence of this transcription factor in 3D culture 
for either fetal progenitor or adult tenocytes (Fig. 3B). The 
addition of ascorbic acid did not change the expression of 
tenomodulin or scleraxis (data not shown).
Cell Population Homogeneity and Stability: 
Flow Cytometry and Karyotyping
The cells showed a homogenous population distribu-
tion at all tested passages, and there was no shift in the 
expression of the observed surface markers. hFPTs stained 
positive for the fibroblast marker D7-fib, for the cell adhe-
sion marker CD90, and for the coreceptor of the TGF-b 
superfamily CD105. There was no discernible contami-
nating subpopulation enrichment, as seen by the negative 
macrophage/neutrophil marker CD14 and hematopoietic/
endothelial cell marker CD34. As expected, the proteins 
of MHC class II (HLA- DR, DP, DQ) were not pres-
ent, while the ones from MHC class I (HLA-A, B, C) 
were mildly positive. The particular MHC class I protein 
HLA-G was not present (Fig. 4A).
hFPTs presented a male karyotype as seen by the pres-
ence of both X and Y chromosomes, and the quality was 
very good at all passages tested with a resolution of 500 
G-bands. At passage 3, on the 60 metaphases tested, 57 were 
normal, and there was one nonclonal numerical abnor-
mality observed during experimentation. Two metaphases 
presented structural abnormalities with a possible dele-
tion of terminal short arm of chromosome 19. Therefore 
an additional 40 supplementary metaphases were tested 
for chromosome 19 without observation of other deletion. 
At passage 6, there was no clonal abnormality. Fifty-six 
metaphases were considered normal, one with numeri-
cal abnormality and three with structural abnormalities. 
At passage 12, the 60 metaphases presented all a normal 
karyotype. For each passage, the karyotype was always 
46, XY. No mosaicism was detected at any passages, and 
with 60 metaphases tested for each passage, the risk of 
mosaicism remains smaller than 5% with a 0.95 confi-
dence level as demonstrated by Hook (24) (Fig. 4B).
Phenotypic Stability With Osteogenic- 
or Adipogenic-Inducing Conditions
After 3 weeks of osteogenic induction, hFPTs remained 
stable, and there was no mineral deposition as shown 
with the Alizarin red and the von Kossa stainings, which 
both remained negative. Both of the adult stem cells 
derived from adipose tissue and bone marrow (ASCs 
and BM-MSCs) cultured under the same conditions 
deposited phosphate and calcium matrix as expected. A 
similar observation was made for adipogenic induction 
with hFPTs being negative for the Oil red O staining, 
while ASCs and BM-MSCs presented lipid accumula-
tion (Fig. 5).
Biocompatibility in Porous Scaffold and Gel Matrix
Twenty-four hours after seeding, hFPTs demonstrated 
a good biocompatibility with commercial horse colla-
gen as indicated using the LIVE/DEAD assay. The cells 
were homogeneously dispersed, they could attach to the 
scaffold, and more than 95% were metabolically active 
(green). Several time points were evaluated, and this 
viability was still found after 14 days. Once cells were 
successfully attached to the matrix (1 h), it was possible 
to rinse the membrane multiple times with PBS with no 
cell detachment seen. In contrast, cells seeded in PBS 
were mostly alive, but remained round and could not 
attach without standard growth medium. hFPTs could be 
homogeneously dispersed in a 0.8% HA gel by using a 
displacement pipette. They did not need growth medium 
and could be directly mixed in PBS or NaCl before being 
dispersed uniformly throughout a viscous gel matrix. 
More than 95% of the cells were alive and metabolically 
active when conserved for 24 h at 4°C. After 72 h, there 
was an increase in dead cells, and the overall viability 
approached 70% (Fig. 6).
Stimulating Ability of hFPTs Towards hATs
In vitro cell culture models for tendon regeneration 
can provide general results on dose response. Such mod-
els may lead to crucial preclinical information for critical 
assessment of potential responses of injury in vivo. The 
results within the coculture assay showed a dose-depen-
dent stimulation of hFPTs on adult tenocytes. A quan-
tity of 10,000 cells per Transwell seemed insufficient to 
stimulate adult tenocytes (0% increase, SD 2.3%, n = 3). 
But with higher amounts of cells, between day 3 and 
17, there was a mean increase of 10% (SD 1.3%, n = 3) 
of the metabolic activity of adult tenocytes with 50,000 
hFPTs per Transwell and of 25% (SD 3.8%, n = 3) with 
100,000 hFPTs per Transwell, compared to an absence of 
hFPTs (Fig. 7). The increased global activity means that 
the number of adult cells was increased or that the meta-
bolic activity per cell was increased, or that both were 
simultaneous.
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DISCUSSION
In case of tendon injury, the major negative outcomes 
are the presence of scar tissue and adherence between 
tendon and its surrounding structures. Fetal tendon heals 
in a different manner, without fibrotic tissue or adhesion. 
The differences seen between fetal regenerative healing 
and adult reparative healing relies probably on different 
cytokine profiles. The idea to use isolated cytokines is 
appealing; however, tissue healing is a complex process 
with multiple interactions between the different cytokines, 
and there is most likely a defined balance to be found to 
ameliorate tendon healing (8). Nevertheless, fetal cells, 
which naturally present such a tuned balance of cytokines 
and which moreover are supposed to be themselves the 
effectors of scarless healing (32), could be optimized for 
a unique cell source for therapeutic use.
To be compatible with a potential clinical use in the 
future, it is crucial to be in accordance with the laws and 
regulations. Tissues and cells for clinical use are regu-
lated nationally in most countries worldwide. In the pres-
ent case, the tissue was obtained as an organ donation, 
which is registered with Swissmedic (Swiss Agency 
for Therapeutic Products) in a Federal Transplantation 
Program and with respect to the Law for Transplantation 
RS810.21 of Switzerland and its related directives on 
research with human subjects. Moreover, it was possible 
to integrate current good manufacturing practice (GMP) 
for cell processing for the creation of the parental cell 
bank, which is of primary importance. Banking cells 
allows the creation of an off-the-shelf stock, which pres-
ents a major advantage to have cells available easily and 
rapidly for their use. In parallel to the legal aspects, the 
Figure 4. hFPT population homogeneity and genetic stability. Cell surface proteins tested by flow cytometry for human fetal progeni-
tor tenocytes (hFPTs) at passage 6 (A). Karyotyping of hFPTs at low and high passages with low cell culture seeding protocols (B).
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Figure 5. hFPT phenotypic stability with inducing conditions (compared to ASCs and BM-MSCs). Osteogenic and adipogenic dif-
ferentiations of fetal progenitor tenocytes (hFPTs), adipose-derived stem cells (ASCs), and bone marrow-derived mesenchymal stem 
cells (BM-MSCs) over 21 days of induction. Osteogenic induction yields calcified nodules or lipid accumulation for BM-MSCs and 
ASCs, which are in brown-black with von Kossa staining (phosphate deposition) and in red with Alizarin red staining (calcium deposi-
tion). Adipogenic induction yields lipid accumulation for BM-MSCs and ASCs, which are in red with Oil red O staining. No matrix 
deposition or lipid accumulation seen for hFPTs. Scale bars: 100 μm.
Figure 6. hFPT biocompatibility within delivery systems. Biocompatibility of human fetal progenitor tenocytes (hFPTs) with porous 
collagen scaffold and hyaluronic acid gel (0.8%) the day following seeding (D1) and again after 14 days (D14) for porous scaffold and 
3 days (D3) for gel. Metabolically active live cells appear in green and damaged dead cells in red. Scale bars: 100 μm.
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cells are expected to present features such as good prolif-
eration capacity, good stability, and possibility of long-
term storage.
The culture of hFPTs was rapid with a minimal dou-
bling time of approximately 30 h in maximal growth 
period and a mean doubling time in passage 10 still more 
rapid than for hATs in passage 4. hFPTs only required 
very basic culture conditions, without need of specific 
growth factors, which permits inexpensive and easier 
growth conditions compared to other cell types such as 
MSCs, which necessitate demanding conditions for 
upscaling cells in an undifferentiated state or directing 
them in a specific phenotype. The overall rate of prolifer-
ation was very steady up to passage 9, even with low ini-
tial seeding densities. This long stability can probably be 
explained as hFPTs were obtained from a young tissue of 
14 weeks gestation. Even if the cells had slightly slower 
proliferation at much higher passages, the morphology 
and karyotype accomplished at passage 12 did not show 
any abnormalities. A major advantage of progenitor cells 
is the possibility to expand them to create a large work-
ing cell bank and therefore an unlimited off-the-shelf 
reserve. An average of 3.72 population doublings per 
passage up to passage 9 means that at each passage, it is 
possible to increase the number of cells by a factor 13.18-
fold (=23.72). If we imagine limiting all clinical work with 
the cells at passage 6 (two thirds of the observable signs 
of cell aging), this would lead to an increase by almost 
400,000-fold (13.185) the initial number of cells banked 
at passage 1. Thus, we can estimate a total of 1.96 × 1014 
cells at the end of passage 6 if the entire cell bank was 
expanded. Estimating approximately 1 million hFPTs per 
Figure 7. Stimulating ability of hFPTs. Metabolic activity of human adult tenocytes (hATs) stimulated by various amounts of irradi-
ated human fetal progenitor tenocytes (hFPTs) through a coculture with Transwell inserts. Experimentation done three times and in 
triplicate with average and standard deviation indicated.
Figure 8. hFPT cell bank processing and capacity. Starting with one biopsy from fetal Achilles tendon, it was possible to create a 
cell bank of 50 vials with 10 million human fetal progenitor tenocytes (hFPTs) each. Based on growth capacity of hFPTs, more than 
100 million treatments could be potentially created with cells at the end of passage 6.
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treatment protocol, it would be possible to create more 
than 100 million treatments (Fig. 8). These estimations 
are hypothetical, but are based on clinical experience with 
our hospital for treatment of burns and wounds (between 
270,000 and 540,000 cells were used per 9 cm × 12 cm 
scaffold for biologic bandages for wound healing), and 
it shows the potential of such a cell line when correctly 
banked for clinical use (15,23,45).
Our results show that it was possible to conserve the 
cells at −80°C for short-term conservation (with more 
than 95% survival over 4 to 10 months) or at −165°C in 
the vapor phase of liquid nitrogen for long-term storage 
(with 90–95% survival over 30 to 36 months). Moreover, 
there was no delay in the growth of frozen cells as the 
doubling times to reach confluency were very close to 
what was found with cells cultured at the same passage 
from enzymatic detachment. These results were obtained 
with standard cryosolution, and the period of conserva-
tion is probably much longer, as we have been able to 
conserve other progenitor cells at −165°C for more than 
15 to 20 years with this manner (e.g., skin progenitor 
cells, unpublished data).
There is still no real specific tendon marker in the lit-
erature (51), so it is preferable to detect the presence of 
a pattern of several proteins, which are not specific, but 
nevertheless characteristic of tendon tissue. It was the 
case in this study and the tenocyte status was confirmed 
for hFPTs with the presence of type I collagen, teno-
modulin, and scleraxis observable in monolayer culture, 
alongside with a morphology very similar compared to 
adult tenocytes. Concerning morphology, it is noticeable 
that fetal tenocytes present a more rounded morphology 
within tendon in vivo during development and at low 
ages (52). However, when placed in 2D culture, fetal pro-
genitor tenocytes present a spindle-shaped morphology 
comparable to the one seen with older cells, even at low 
passages. Concerning the markers, type I collagen is an 
extracellular matrix component, and the strong cytoplas-
mic staining, which was observed, could be explained by 
the presence of type I procollagen. Type I procollagen 
shares the same amino acid sequence as type I collagen 
with the presence of propeptides at both terminal ends. 
It is synthesized in the cell before being converted to 
type I collagen by cleavage of propeptide during secre-
tion in the extracellular matrix (6,25). Interestingly, when 
cultured as microtissue pellets, there were some differ-
ences between fetal progenitor and adult cells. The global 
deposition of matrix was visually increased with hFPTs 
compared to hATs, and there was a deposition of type 
I collagen in hFPT pellets, while it was not possible to 
detect this protein in 3D culture from hATs cultured under 
the same conditions. The addition of ascorbic acid (impli-
cated in collagen synthesis) allowed the synthesis of type 
I collagen in both fetal and adult pellets, but still in lower 
quantities for hATs than for hFPTs. Fetal and adult ten-
dons are known to be able to secrete different types of 
matrix, notably in the case of tendon healing. In adult 
healing, type I collagen peaks only after several weeks to 
replace the temporary fixative matrix (49), while in fetal 
healing the regenerated tendon appears rapidly indiscern-
ible from unwounded tendons (8). Thus, it is possible 
that human progenitor tenocytes secrete preferably type 
I collagen, while adult cells are more turned toward other 
proteins. Further investigations would be necessary to 
compare the differences between the extracellular matrix 
compositions, which could be linked with the regenera-
tive properties of fetal cells versus the reparative abilities 
of adult cells, and a recent study in sheep highlighted dif-
ferences in morphological and molecular changes from 
fetal development to adult (48). Tenomodulin and scler-
axis have both proven to have an implication in tendon 
development, as mice lacking either one have shown 
defects in tendon structure (18,36). In 3D culture, teno-
modulin was secreted in both young and old cell lines. 
On the other hand, it was not possible to detect the pres-
ence of scleraxis in 3D culture in either fetal progenitor 
or in adult cells. Taylor et al. found a similar situation 
with a significantly reduced expression of scleraxis in 
3D cell culture (51). They hypothesized that scleraxis is 
important in the early steps of tendon development, but 
that once the phenotype is acquired there is no further 
change in its expression. The similar expression of scler-
axis between normal and diseased tendons supports these 
assumptions (51).
The surface markers of hFPTs seen with flow cytome-
try indicated a homogenous cell population. As expected, 
the overall profile was similar to fibroblastic adherent 
cells (positive for D7-fib and CD90). Potential contami-
nating subpopulations like hematopoietic or endothelial 
cells were not found (CD34 and CD14), which is impor-
tant as it is known that the reduction of such cells (e.g., 
T lymphocytes) prevents significant graft-versus-host 
disease reactions (42). There was no shift in the expres-
sion of the surface markers between low and high pas-
sages, indicating a good stability. The presence of CD105 
was really interesting as it increases the stability of the 
cells in the tenogenic phenotype. Indeed, it has recently 
been demonstrated that a lack of this protein in tenocytes 
leads to more chondrogeneration in healing tendon than 
when this protein is present (4).
hFPTs exhibited, as expected, a lack of MHC class 
II proteins (HLA-DR, DP, DQ), while MHC class I 
(HLA-A, B, C) was mildly present. This profile is very 
close to the one of MSCs (29). T lymphocytes are known 
to drive allograft rejection through HLA recognition, and 
the presence of MHC class I proteins on the surface of 
a cell should normally trigger an immune reaction from 
CD8+ T cells. Nonetheless, it has largely been proven 
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that MSCs, even if they present MHC class I antigens, 
have immune-modulating effects and that they are able 
to be grafted with lack of immunological response. 
Indeed, they possess the ability to inhibit proliferation 
of T lymphocytes in vitro (29) and have also been well 
tolerated in vivo, notably in primates, even in the case 
of MHC mismatch (7,17). Neonatal foreskin cells found 
in the commercial product Apligraft also present a simi-
lar MHC profile and have also been well tolerated (50). 
The tolerance seen with these examples would indicate 
that the mechanism is not fully understood and that some 
allogenic cell types, although presenting HLA proteins, 
can be used for transplantation without immunosuppres-
sion. There is multiple evidence that fetal cells behave 
in the same manner with a capacity to modulate immune 
reaction. One of the most important observations sup-
porting this is during gestation itself. It has been shown 
that even if paternal HLA-C are recognized during preg-
nancy, there is no harm to the fetus (38). The presence of 
HLA-G has been proposed as a potential modulator, as 
these proteins are elevated on fetal cells in contact with 
maternal tissue and have been shown to be able to inhibit 
different lymphocytes (12,41,47). hFPTs did not express 
these particular MHC class I proteins, but this is none-
theless not the only mechanism of immunomodulation 
in fetal tissue. Fetal fibroblasts and keratinocytes pres-
ent an immunosuppressive activity and are able to inhibit 
lymphoproliferation, notably through their expression of 
indoleamine 2,3-dioxygenase (IDO) (59). Our past clini-
cal trials have also illustrated an excellent tolerance for 
fetal cells. Biologic bandages containing fetal fibroblasts 
lead to improved outcomes in burn and wound healing, 
and even if there was no engraftment long term, multiple 
applications did not initiate immune reactions (15,23).
Altered cell differentiation is sometimes thought to 
play a role in the etiology of tendinopathies (16), as 
calcification and appearance of lipid droplets (normally 
not seen in tendons) are factors found in tendinopathies, 
which can precede spontaneous rupture of tendons (28). 
To use cell therapy for tendon treatment, it is then of 
primary importance to have a cell line with a stable 
phenotype, to avoid drift to osteogenic or adipogenic 
phenotypes. While ASCs and BM-MSCs showed dif-
ferentiation into osteogenic or adipogenic phenotypes 
under inducing conditions, hFPTs demonstrated a very 
high stability in their phenotype without any sign of min-
eral or lipid accumulation. These results are particularly 
encouraging as it could prevent the differentiation of the 
cells and the appearance of calcification or lipid accu-
mulation often seen in vivo with other cell types. MSCs, 
either from adipose tissue or from bone marrow, have 
been employed for tendon regeneration in various animal 
models (31), and even in a human clinical trial (19). In 
most of the cases, MSCs lead to improved outcomes, but 
they could not attain the quality found with fetal healing 
(8,58). Furthermore, there is still concern about the sta-
bility of MSCs to act as tenocytes when used in tendon 
repair. In a study conducted by Awad et al., the use of 
MSC–collagen composites improved the biomechanical 
parameters of the repaired tendon, but lead to the for-
mation of bone in the repair site in 28% of the grafted 
tendons versus 0% in the natural repair control group (5). 
Bi et al. also warned that BM-MSCs expanded in vitro 
before transplantation into mice formed bone rather than 
tendon tissue and that the use of such cells could poten-
tially lead to calcifications. In contrast, they showed that 
the use of the recently discovered tendon stem/progenitor 
cells (TSPCs) avoided this problem with a phenotype 
more tuned into tendon production. However, the har-
vesting of autologous TSPCs does not seem possible for 
clinical use as there is not an easily available source (9). 
Embryonic stem cells (ESCs) have also been tested in 
vivo, and Chen et al. have proposed a manner to first 
differentiate ESCs into MSCs before tendon treatment to 
avoid the risk of teratoma formation (13). More recently, 
induced pluripotent stem cells (iPSCs) improved the out-
comes of tendon healing in a study (57). However, ESCs 
and iPSCs are also inducible cells and still present the 
same risk of dedifferentiation as MSCs. Differentiated 
cells such as human autologous tenocytes could present 
good stability, but as for TSPCs, there is a lack of an eas-
ily available source for harvesting, and this would also 
require a biopsy and lengthy culture period before clini-
cal use would be possible. hFPTs present both advantages 
of a strong overall stability (phenotype and karyotype), 
along with an off-the-shelf availability whenever needed, 
which gives support for these cells as a potential source 
in clinical use.
Different clinically acceptable delivery systems would 
be critical to assure localized and targeted treatments. 
hFPTs had the ability to positively interact both with gel 
and porous matrix and therefore could provide interesting 
delivery modes that are routinely used in the clinic. On 
one side, injectable cell preparations capable of stimu-
lating tendon regeneration could be particularly inter-
esting to treat tendinopathies and simple acute injuries. 
The ability of hFPTs to survive in HA gel overnight (or 
even up to 3 days) at 4°C could provide an interesting 
logistic solution. It would be easy to prepare the formula-
tion on the day before an intervention by removing cells 
from the frozen-stored bank, rinsing them with PBS or 
NaCl to eliminate undesired products, mixing them with 
gel and keeping the product at 4°C for transport. On the 
other hand, engineered tendon constructs would be use-
ful for resistant degenerative or extended acute injuries, 
when filling bulk tissue defects with material is required 
(40). hFPTs can be uniformly and efficiently integrated 
into scaffold, and a rinsing step before delivery allows to 
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remove undesired products without detaching cells. The 
product can be delivered almost immediately or kept in 
culture for longer periods.
Tendon healing is known to be a long process in part 
driven by adult tenocytes. Our in vitro model of coculture 
has proven that hFPTs could stimulate adult tenocytes, 
which is interesting as an increase in their global activity 
could potentially accelerate the overall process. In addi-
tion, studies and literature indicate that wound stimulation 
provided by cell therapy with fetal progenitor cells could 
potentially provide a scarless healing with the absence 
of fibrotic tissue. An in vivo study to show safety and 
efficacy would be the next step to bring this cell therapy 
closer to the clinic.
CONCLUSION
hFPTs have been shown to be a unique stable cell 
source that can be produced under stringent current GMP 
manufacturing. They present a remarkable genetic and 
phenotypic stability and are able to conserve their teno-
genic nature even in the presence of inductive conditions 
toward other phenotypes. The possibility to create rap-
idly a large cell bank to obtain off-the-shelf reserves is 
ideal for cell therapy and tissue engineering. Moreover, 
the cells show a good interaction both with porous and 
gel scaffolds for clinical preparations and delivery. As 
the cells are all derived from the same organ donation, 
it is also possible to include within the process extensive 
screening easily adaptable to GMP cell banking condi-
tions. Finally, their ability to stimulate the activity of 
adult tenocytes is of importance as it could lead to a more 
rapid healing in vivo. The in vivo model chosen for fur-
ther evaluation should also allow distinguishing whether 
rapid regenerative healing without scar could be attained 
all the while assuring safety and that no immune reaction 
would be elicited by these particular banked fetal pro-
genitor tenocytes.
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